Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice
Cancer research, 2013•AACR
Most systemic cancer therapies target tumor cells directly, although there is increasing
interest in targeting the tumor stroma that can comprise a substantial portion of the tumor
mass. We report here a synergy between two T-cell therapies, one directed against the
stromal tumor vasculature and the other directed against antigens expressed on the tumor
cell. Simultaneous transfer of genetically engineered syngeneic T cells expressing a
chimeric antigen receptor targeting the VEGF receptor-2 (VEGFR2; KDR) that is …
interest in targeting the tumor stroma that can comprise a substantial portion of the tumor
mass. We report here a synergy between two T-cell therapies, one directed against the
stromal tumor vasculature and the other directed against antigens expressed on the tumor
cell. Simultaneous transfer of genetically engineered syngeneic T cells expressing a
chimeric antigen receptor targeting the VEGF receptor-2 (VEGFR2; KDR) that is …
Abstract
Most systemic cancer therapies target tumor cells directly, although there is increasing interest in targeting the tumor stroma that can comprise a substantial portion of the tumor mass. We report here a synergy between two T-cell therapies, one directed against the stromal tumor vasculature and the other directed against antigens expressed on the tumor cell. Simultaneous transfer of genetically engineered syngeneic T cells expressing a chimeric antigen receptor targeting the VEGF receptor-2 (VEGFR2; KDR) that is overexpressed on tumor vasculature and T-cells specific for the tumor antigens gp100 (PMEL), TRP-1 (TYRP1), or TRP-2 (DCT) synergistically eradicated established B16 melanoma tumors in mice and dramatically increased the tumor-free survival of mice compared with treatment with either cell type alone or T cells coexpressing these two targeting molecules. Host lymphodepletion before cell transfer was required to mediate the antitumor effect. The synergistic antitumor response was accompanied by a significant increase in the infiltration and expansion and/or persistence of the adoptively transferred tumor antigen–specific T cells in the tumor microenvironment and thus enhanced their antitumor potency. The data presented here emphasize the possible beneficial effects of combining antiangiogenic with tumor-specific immunotherapeutic approaches for the treatment of patients with cancer. Cancer Res; 73(11); 3371–80. ©2013 AACR.
AACR